Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: OTC monograph program

This article was originally published in The Tan Sheet

Executive Summary

OTC monograph program: Based on FDA's semi-annual regulatory agenda, monograph documents closest to publication include: a proposed amendment to the monograph on weight control products; a proposed amendment to the internal analgesics monograph on an alcohol warning; and final action on the use of phenolphthalein in OTC laxatives. Documents targeted for early 1998 release include a proposal on OTC adverse reactions reporting, final action on the poison ivy indication in the skin protectant monograph and final action on the use of sodium phosphates in laxatives, as well as a final amendment to the laxatives monograph on phosphates labeling. The agency lists July 1998 as the target date for release of a final rule on standardized OTC labeling and estimates a proposal revising the agency's requirements for internal analgesic label indications will be issued in October 1998. The regulatory agenda, published in the Oct. 29 Federal Register, is required four times a year, but the timetables are often only guess-timates...

OTC monograph program: Based on FDA's semi-annual regulatory agenda, monograph documents closest to publication include: a proposed amendment to the monograph on weight control products; a proposed amendment to the internal analgesics monograph on an alcohol warning; and final action on the use of phenolphthalein in OTC laxatives. Documents targeted for early 1998 release include a proposal on OTC adverse reactions reporting, final action on the poison ivy indication in the skin protectant monograph and final action on the use of sodium phosphates in laxatives, as well as a final amendment to the laxatives monograph on phosphates labeling. The agency lists July 1998 as the target date for release of a final rule on standardized OTC labeling and estimates a proposal revising the agency's requirements for internal analgesic label indications will be issued in October 1998. The regulatory agenda, published in the Oct. 29 Federal Register, is required four times a year, but the timetables are often only guess-timates....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel